Oncology News | pharmaphorum

News

FDA gives AZ the nod for Imfinzi in biliary tract cancer

AstraZeneca's checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited tre

News

Illumina defeats FTC bid to dismantle Grail takeover

A judge in the US has ruled in favour of Illumina in a dispute with the Federal Trade Commission (FTC) over its multibillion-dollar takeover of cancer diagnosis specialist Grail, which had

News

Phase 3 trial confirms Lumakras role in lung cancer

Amgen's pathfinder KRAS inhibitor Lumakras has been shown to be effective in KRAS-mutated non-small cell lung cancer (NSCLC) in a phase 3 trial that should serve as a confirmation study for

News

Jounce setback casts deeper pall over ICOS as cancer target

A phase 2 trial of Jounce Therapeutics' ICOS agonist vopratelimab has ended in failure, casting further doubt about the validity of ICOS as a target for cancer therapies.

News

Novartis extends Kaiku digital patient monitoring partnershi...

Kaiku Health's year-old alliance with Novartis to develop a digital patient monitoring and management (DPPM) system for patients with melanoma is being extended, according to the two partne

News

Merck takeover talks with Seagen have hit a hurdle; report

Merck & Co's negotiations with Seagen over a possible takeover have stalled because the two sides cannot agree on a price, according to Bloomberg, citing people familiar with the matter

FDA gives AZ the nod for Imfinzi in biliary tract cancer

Illumina defeats FTC bid to dismantle Grail takeover

Phase 3 trial confirms Lumakras role in lung cancer

Jounce setback casts deeper pall over ICOS as cancer target

Novartis extends Kaiku digital patient monitoring partnershi...

Merck takeover talks with Seagen have hit a hurdle; report

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks